DNA甲基化抑制剂改善Danon病X连锁相关自噬失败
本研究利用Danon病患者来源的诱导多能干细胞分化的心肌细胞(iPSC-CMs)建立疾病模型,发现X染色体随机失活导致女性患者表型差异,DNA去甲基化剂5-aza-2'-deoxycytidine可重新激活沉默的LAMP2等位基因并改善自噬失败,为个体化iPSC平台用于疾病建模和药物筛选提供依据。
要点
- 女性Danon病表型差异源于X染色体随机失活
- 患者iPSC-CMs重现Danon病组织学特征和自噬失败
- 5-aza-2'-deoxycytidine可重新激活沉默LAMP2并改善自噬失败
核心结论
- iPSC-CMs平台揭示X染色体随机失活对Danon病疾病表型的贡献,并证明DNA甲基化抑制剂可改善自噬失败。
研究设计与样本
- 利用全外显子测序在一个Danon病家系中鉴定LAMP2基因无义突变(c.520C>T,外显子4)。
- 从患病母亲及其2个儿子的体细胞生成iPSC系,并分化为心肌细胞(iPSC-CMs)进行疾病建模。
主要发现
- 患者iPSC-CMs在体外重现Danon病的组织学特征和自噬失败。
- X染色体上野生型和突变型LAMP2等位基因的随机失活是女性患者异常表型的原因。
- 5-aza-2'-deoxycytidine在女性患者iPSC和iPSC-CMs中重新激活沉默的LAMP2等位基因并改善自噬失败。
临床怎么用
- 患者特异性iPSC平台可用于Danon病的疾病建模和药物筛选。
- DNA甲基化抑制剂可能作为女性Danon病的潜在治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Danon disease is an X-linked disorder that leads to fatal cardiomyopathy caused by a deficiency in lysosome-associated membrane protein-2 (LAMP2). In female patients, a later onset and less severe clinical phenotype have been attributed to the random inactivation of the X chromosome carrying the mutant diseased allele. We generated a patient-specific induced pluripotent stem cell (iPSCs)-based model of Danon disease to evaluate the therapeutic potential of Xi-chromosome reactivation using a DNA methylation inhibitor. METHODS: Using whole-exome sequencing, we identified a nonsense mutation (c.520C>T, exon 4) of the LAMP2 gene in a family with Danon disease. We generated iPSC lines from somatic cells derived from the affected mother and her 2 sons, and we then differentiated them into cardiomyocytes (iPSC-CMs) for modeling the histological and functional signatures, including autophagy failure of Danon disease. RESULTS: Our iPSC-CM platform provides evidence that random inactivation of the wild-type and mutant LAMP2 alleles on the X chromosome is responsible for the unusual phenotype in female patients with Danon disease. In vitro, iPSC-CMs from these patients reproduced the histological features and autophagy failure of Danon disease. Administration of the DNA demethylating agent 5-aza-2'-deoxycytidine reactivated the silent LAMP2 allele in iPSCs and iPSC-CMs in female patients with Danon disease and ameliorated their autophagy failure, supporting the application of a patient-specific iPSC platform for disease modeling and drug screening. CONCLUSIONS: Our iPSC-CM platform provides novel mechanistic and therapeutic insights into the contribution of random X chromosome inactivation to disease phenotype in X-linked Danon disease.
引用
- Ng KM, Mok PY, Butler AW, et al. Amelioration of X-Linked Related Autophagy Failure in Danon Disease With DNA Methylation Inhibitor. Circulation. 2016. PMID: 27678261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。